Fresenius Medical Care AG & Co KGaA (FMS) Stock

On December 27, 2024, PAYO, TTDKY, and FMS were included in the Zacks Rank #1 (Strong Buy) list of momentum stocks.

BAD HOMBURG, Germany, Dec. 20, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), a top provider of products and services for kidney disease, will rejoin the DAX 40, Germany's main stock index, starting December 27, 2024. This index tracks the performance of the 40 largest publicly traded companies on the Frankfurt Stock Exchange and represents about 80 percent of the market value of listed companies in Germany.

Fresenius Medical Care is a top provider of dialysis services worldwide, focusing on growth through new ideas, reorganizing its operations, and having a strong presence in over 120 countries.

At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. However, we also keep an eye on the most recent trends in value, growth, and momentum to support our top selections.

No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.

Fresenius Medical Care AG (NYSE:FMS) will hold its Q3 2024 Earnings Conference Call on November 5, 2024, at 8:00 AM ET. Key participants from the company include Dominik Heger, Helen Giza, and Martin Fischer. The call will also feature analysts from various financial institutions, and the operator, Sandra, will welcome everyone to the event.

In the third quarter, we saw a 2% increase in organic revenue, driven by improvements in Care Enablement and Care Delivery. The U.S. dialysis treatment volume growth has turned positive, and we exceeded our savings target for the year, adding an extra EUR 64 million in the third quarter. Both segments have also improved their operating income and margins, with a positive outlook for operating income growth in FY 2024.

At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. However, we also keep an eye on the most recent trends in value, growth, and momentum to support our top selections.

A special session will focus on the latest developments in hemodiafiltration therapy, which may help improve patient results by better removing toxins during dialysis. Researchers and clinical experts from the company will present findings from extensive global databases, highlighting important trends in the causes of kidney failure, heart risks, and treatment methods in various areas.